These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19834613)

  • 1. Sequence and structure signatures of cancer mutation hotspots in protein kinases.
    Dixit A; Yi L; Gowthaman R; Torkamani A; Schork NJ; Verkhivker GM
    PLoS One; 2009 Oct; 4(10):e7485. PubMed ID: 19834613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
    Dixit A; Verkhivker GM
    Comput Math Methods Med; 2014; 2014():653487. PubMed ID: 24817905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MoKCa database--mutations of kinases in cancer.
    Richardson CJ; Gao Q; Mitsopoulous C; Zvelebil M; Pearl LH; Pearl FM
    Nucleic Acids Res; 2009 Jan; 37(Database issue):D824-31. PubMed ID: 18986996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
    Dixit A; Verkhivker GM
    PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
    Dixit A; Torkamani A; Schork NJ; Verkhivker G
    Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated mutations are preferentially distributed in protein kinase functional sites.
    Izarzugaza JM; Redfern OC; Orengo CA; Valencia A
    Proteins; 2009 Dec; 77(4):892-903. PubMed ID: 19626714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication.
    Verkhivker GM
    Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):210-225. PubMed ID: 30339916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein domain-level landscape of cancer-type-specific somatic mutations.
    Yang F; Petsalaki E; Rolland T; Hill DE; Vidal M; Roth FP
    PLoS Comput Biol; 2015 Mar; 11(3):e1004147. PubMed ID: 25794154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The energy landscape analysis of cancer mutations in protein kinases.
    Dixit A; Verkhivker GM
    PLoS One; 2011; 6(10):e26071. PubMed ID: 21998754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of cancer driver mutations in protein kinases.
    Torkamani A; Schork NJ
    Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.
    Baeissa H; Benstead-Hume G; Richardson CJ; Pearl FMG
    Oncotarget; 2017 Mar; 8(13):21290-21304. PubMed ID: 28423505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER.
    Gallion J; Wilkins AD; Lichtarge O
    Pac Symp Biocomput; 2017; 22():414-425. PubMed ID: 27896994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer driver mutations in protein kinase genes.
    Torkamani A; Verkhivker G; Schork NJ
    Cancer Lett; 2009 Aug; 281(2):117-27. PubMed ID: 19081671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Atypical and Eukaryotic Protein Kinases.
    Kanev GK; de Graaf C; de Esch IJP; Leurs R; Würdinger T; Westerman BA; Kooistra AJ
    Trends Pharmacol Sci; 2019 Nov; 40(11):818-832. PubMed ID: 31677919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
    Bailey FP; Andreev VI; Eyers PA
    Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular basis of targeting protein kinases in cancer therapeutics.
    Tsai CJ; Nussinov R
    Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KinMutBase: a registry of disease-causing mutations in protein kinase domains.
    Ortutay C; Väliaho J; Stenberg K; Vihinen M
    Hum Mutat; 2005 May; 25(5):435-42. PubMed ID: 15832311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProKinO: a unified resource for mining the cancer kinome.
    McSkimming DI; Dastgheib S; Talevich E; Narayanan A; Katiyar S; Taylor SS; Kochut K; Kannan N
    Hum Mutat; 2015 Feb; 36(2):175-86. PubMed ID: 25382819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.